Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ProQR Therapeutics N.V. (PRQR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
3.4200-0.0400 (-1.16%)
At close: 04:00PM EDT
3.4300 +0.01 (+0.29%)
After hours: 05:44PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Performance Outlook
Previous Close3.4600
Open3.4500
Bid3.3900 x 1100
Ask3.5000 x 1200
Day's Range3.2600 - 3.4700
52 Week Range0.5300 - 3.8500
Volume706,471
Avg. Volume1,360,014
Market Cap244.306M
Beta (5Y Monthly)0.12
PE Ratio (TTM)N/A
EPS (TTM)-1.1200
Earnings DateMar 29, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.21
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PRQR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ProQR Therapeutics N.V.
    QURE: Lowering target price to $24.00UNIQURE NV has an Investment Rating of BUY; a target price of $24.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

    LEIDEN, Netherlands & CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully defended against two oppositions that were filed against a key patent for its ADAR-mediated RNA editing platform Axiomer®. The oppositions were filed in February 2021 with the European Patent Office (EPO) by two separate strawmen against ProQR’s granted patent EP 3

  • GlobeNewswire

    ProQR to Present at Upcoming Scientific and Industry Conferences

    LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced several presentations highlighting the Company’s proprietary Axiomer® RNA editing technology platform at upcoming scientific and industry conferences, including the 8th annual Oligonucleotide and Precision Therapeutics (OPT) Congress, March 13-14, 2023 in Boston, MA, U.S.; RNA Leaders

  • GlobeNewswire

    ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a virtual R&D event on Wednesday, March 29, 2023 from 10:00 am until 12:30 pm EDT, including an Analyst Q&A session with members of the ProQR Management Team. During the event, the Company will showcase its proprietary Axiomer® RNA-editing technology platform

Advertisement
Advertisement